176 related articles for article (PubMed ID: 24122232)
1. Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer.
Zhang C; Ye L; Guan S; Jin S; Wang W; Sun S; Lee KH; Wei J; Liu B
Tumour Biol; 2014 Mar; 35(3):2047-51. PubMed ID: 24122232
[TBL] [Abstract][Full Text] [Related]
2. Anti-p16 autoantibodies may be a useful biomarker for early diagnosis of esophageal cancer.
Jin Y; Guan S; Liu L; Sun S; Lee KH; Wei J
Asia Pac J Clin Oncol; 2015 Dec; 11(4):e37-41. PubMed ID: 24811068
[TBL] [Abstract][Full Text] [Related]
3. Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?
Liu L; Liu N; Liu B; Yang Y; Zhang Q; Zhang W; Yu P; Jin Y; Guo J; Guan S; Sun S; Miao L; Wei J
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1737-42. PubMed ID: 22699933
[TBL] [Abstract][Full Text] [Related]
4. A study of circulating anti-CD25 antibodies in non-small cell lung cancer.
Ye L; Li X; Sun S; Guan S; Wang M; Guan X; Lee KH; Wei J; Liu B
Clin Transl Oncol; 2013 Aug; 15(8):633-7. PubMed ID: 23263913
[TBL] [Abstract][Full Text] [Related]
5. Detection of Circulating Antibodies to p16 Protein-Derived Peptides in Hepatocellular Carcinoma.
Xu Y; Gu L; Wang J; Wang Z; Zhang P; Zhang X
Lab Med; 2020 Nov; 51(6):574-578. PubMed ID: 32195537
[TBL] [Abstract][Full Text] [Related]
6. Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer.
Wang W; Guan S; Sun S; Jin Y; Lee KH; Chen Y; Wei J
Tumour Biol; 2014 May; 35(5):4901-5. PubMed ID: 24453033
[TBL] [Abstract][Full Text] [Related]
7. Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer.
Zhao H; Zhang X; Han Z; Xie W; Yang W; Wei J
Sci Rep; 2018 Jun; 8(1):9847. PubMed ID: 29959381
[TBL] [Abstract][Full Text] [Related]
8. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
[TBL] [Abstract][Full Text] [Related]
9. Increased Levels of Circulating Anti-ANXA1 IgG Antibody in Patients with Non-Small Cell Lung Cancer.
Liang T; Han Z; Zhao H; Zhang X; Wang Y
Clin Lab; 2018 Jun; 64(6):895-900. PubMed ID: 29945332
[TBL] [Abstract][Full Text] [Related]
10. Change of circulating antibodies against CD25-derived peptide antigen in hepatocellular carcinoma.
Wang J; Xu Y; Zhao H; Zhang X
J Cancer Res Ther; 2017; 13(5):813-816. PubMed ID: 29237909
[TBL] [Abstract][Full Text] [Related]
11. Circulating antibodies to p16 protein-derived peptides in breast cancer.
Chen C; Huang Y; Zhang C; Liu T; Zheng HE; Wan S; Sun S; Meng Q; Chen Y; Wei J
Mol Clin Oncol; 2015 May; 3(3):591-594. PubMed ID: 26137272
[TBL] [Abstract][Full Text] [Related]
12. The Combination of IgA and IgG autoantibodies against Transcriptional Intermediary Factor-1γ contributes to the early diagnosis of Lung Cancer.
Yu L; Lin X; Zhang L; Wu Q; Zhang S; Chen D; Pan X; Huang Y
Int J Med Sci; 2020; 17(11):1561-1568. PubMed ID: 32669959
[No Abstract] [Full Text] [Related]
13. Detecting of p16 Autoantibody as a Potential Early Diagnostic Serum Biomarker in Patients with Cervical Cancer.
Huangfu M; Liu L; Xu S; Li S; Jiang K; Sun B; Lee KH; Sun S
Clin Lab; 2016; 62(6):1117-20. PubMed ID: 27468574
[TBL] [Abstract][Full Text] [Related]
14. Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma.
Guan S; Liu B; Zhang C; Lee KH; Sun S; Wei J
Clin Transl Oncol; 2013 Oct; 15(10):825-9. PubMed ID: 23423807
[TBL] [Abstract][Full Text] [Related]
15. FOXP3 autoantibody as a potential early prognostic serum biomarker in patients with cervical cancer.
Xu S; Huangfu M; Jia X; Song X; Sun B; Lee KH; Liu L; Sun S
Int J Clin Oncol; 2015 Oct; 20(5):982-8. PubMed ID: 25681877
[TBL] [Abstract][Full Text] [Related]
16. Circulating anti-p16a IgG autoantibodies as a potential prognostic biomarker for non-small cell lung cancer.
Zhao H; Zhang X; Han Z; Wang Y
FEBS Open Bio; 2018 Nov; 8(11):1875-1881. PubMed ID: 30410866
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
Li P; Shi JX; Xing MT; Dai LP; Li JT; Zhang JY
Tumour Biol; 2017 Oct; 39(10):1010428317711662. PubMed ID: 29022480
[TBL] [Abstract][Full Text] [Related]
18. Development of a panel of serum IgG and IgA autoantibodies for early diagnosis of colon cancer.
Chen M; Lin X; Zhang L; Yu L; Wu Q; Zhang S; Xue F; Huang Y
Int J Med Sci; 2020; 17(17):2744-2750. PubMed ID: 33162802
[No Abstract] [Full Text] [Related]
19. An Autoantibody Against Human DNA-Topoisomerase I Is a Novel Biomarker for Non-Small Cell Lung Cancer.
Wu WB; Yie SM; Ye SR; Xie K; Zhang JB; Cao M; Chen J; He X; Ma XL; Zhang J
Ann Thorac Surg; 2018 Jun; 105(6):1664-1670. PubMed ID: 29453962
[TBL] [Abstract][Full Text] [Related]
20. Study of circulating IgG antibodies to BIRC5 and MYC in non-small cell lung cancer.
Ye L; Wang W; Chen C; Meng Q; Yu Y
FEBS Open Bio; 2015; 5():809-12. PubMed ID: 26566475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
